A phase IB biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer (MDA2013-01-02)
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,340,619
Award facts
- Opportunity
-
- TORFPB Solicitation number
- Contract value 100% obligated
- $1,340,619.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77230, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $39,856 | |
| Other Administrative Action | $0 | |
| Funding Only Action | -$40,877 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $290,877 | |
| Other Administrative Action | $0 | |
| Original award | $1,050,763 |
About this award
The National Cancer Institute issued a $1,340,619.47 delivery order to The University of Texas MD Anderson Cancer Center on September 20, 2013, for a Phase IB biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer under the Cancer Prevention Agent Development Program 2012–2017 IDIQ.
The Cancer Prevention Agent Development Program supports early-phase clinical research in cancer prevention. Place of performance is Houston, TX. The order is priced on a cost, no-fee basis with a completion date of March 19, 2020.
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 20, 2013.
How much is contract HHSN26100003 worth?
The government has obligated $1,340,619 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award